CompletedNot applicableNCT03025945

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Studying Cystoid macular dystrophy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Intuor Technologies, Inc.
Principal Investigator
Sean McCafferty, MD
Arizona Eye Consultants
Intervention
Nepafenac 0.3%(drug)
Enrollment
662 enrolled
Eligibility
18 years · All sexes
Timeline
2013 – 2017

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03025945 on ClinicalTrials.gov

Other trials for Cystoid macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Cystoid macular dystrophy →

← Back to all trials